PerkinElmer
check quantity

IVISbrite D-Luciferin Bioluminescent Substrate in RediJect Solution (XenoLight)

IVISbrite D-Luciferin Bioluminescent Substrate in RediJect Solution (RediJect D-Luciferin K+ salt) is a bioluminescent in vivo substrate in a convenient ready-to-use, pre-formulated injectable format developed by PerkinElmer to fit your laboratory workflow.

For research use only. Not for use in diagnostic procedures.

Part Number
List Price
Your Price
Quantity
770504
357.00 USD
 
more
Buy Now

Please enter valid quantity

Please log in to add favorites.

NULL OR EMPTY CART

Overview

With PerkinElmer’s IVISbrite D-Luciferin Bioluminescent Substrate in RediJect Solution you can ensure a reproducible result by minimizing variability in formulation, minimizing freeze/thaw and controlling batch to batch variation. With thousands of publications and millions of mice imaged, we have formulated its substrates to fit common workflow patterns and optimize results. You are free to concentrate on animal handling and biology.

  • Pre-formulated, batch controlled D-Luciferin for in vivo use
  • Save substantial time and effort by minimizing pre-imaging preparation steps
  • Dispensed to image 5 animals per vial (10 vials/kit)
  • In vivo imaging quality, validated on IVIS® imaging systems

Specifications

Luciferase Classification Firefly
Product Brand Name IVISbrite
Quantity in a Package Amount 1.0 Units
Shipping Condition Dry Ice
Type Luciferin
Unit Size 10 vials
Resources, Events & More
  • All

Ebook

In Vivo Imaging Solutions eBook

Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.

PDF 4 MB

White Paper

The Role of In Vivo Imaging in Drug Discovery and Development

The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.

PDF 547 KB